Teva Pharmaceutical Industries (TEVA) Shares Outstanding (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Shares Outstanding (Entity) for 18 consecutive years, with $1.3 billion the latest figure, recorded in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 1.44% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 1.44% YoY) and the FY2025 annual result came in at $1.3 billion, up 1.37% from the prior year.
• Shares Outstanding (Entity) climbed to $1.3 billion in Q1 2026 per TEVA's latest filing, from $1.3 billion in the prior quarter.
• Over the last five years, Shares Outstanding (Entity) for TEVA reached as high as $1.3 billion in Q1 2026 and fell as low as $1.1 billion in Q2 2022.
• A 5-year average of $1.2 billion and a median of $1.2 billion in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) declined 8.19% — and 2023, when it rose 10.54%.
• Year by year, Shares Outstanding (Entity) stood at $1.2 billion in 2022, then increased by 0.82% to $1.2 billion in 2023, then advanced by 1.06% to $1.2 billion in 2024, then climbed by 1.37% to $1.3 billion in 2025, then increased by 1.11% to $1.3 billion in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $1.3 billion, $1.3 billion, and $1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.